Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28145458 | 0.86 | LIMK1 (0.33) | CHEK1 | |
| SCHEMBL11597508 | 0.77 | CYP3A4 (0.41) | CHEK1 | |
| SCHEMBL11597505 | 0.76 | — | — | |
| SCHEMBL11597991 | 0.75 | — | — | |
| SCHEMBL28151044 | 0.74 | DAO (0.35) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL435598 | 0.71 | LIMK1 (0.37) | ALDH1A1 | |
| SCHEMBL2054828 | 0.71 | — | — | |
| SCHEMBL536664 | 0.71 | CHUK (0.34) | ALDH1A1 | |
| SCHEMBL27870444 | 0.71 | ATR (0.33) | ALDH1A1 | |
| SCHEMBL28190077 | 0.70 | MAPT (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262298-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-21 | — | — | US | disclosed |
| US-20250163417-A1 | COMPOSITIONS AND METHODS FOR IMPROVING STRAND BIASED | ALNYLAM PHARMACEUTICALS,INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-12173287-B2 | Compositions and methods for improving strand biased | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| EP-4242212-A2 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | Takeda Pharmaceutical Company Limited (JP) | 2023-09-13 | — | — | EP | disclosed |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I (CZ) | 2022-05-26 | — | — | US | disclosed |
| US-5610300-A | ANTIVIRAL, ANTIPROLIFERATIVE, ANTISENSE TECHNOLOGY, DIAGNOSIS | CIBA-GEIGY CORPORATION (US) | 1997-03-11 | — | — | US | disclosed |
| US-5461152-A | Nucleoside intermediates for antisense oligonucleotides, antiviral agents | CIBA-GEIGY CORPORATION (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0319228-B1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1994-11-02 | — | — | EP | disclosed |
| EP-0577558-A2 | Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates | CIBA-GEIGY AG (CH) | 1994-01-05 | — | — | EP | disclosed |
| US-5247085-A | Phosphonate containing purine compounds | BEECHAM GROUP P.L.C. (GB) | 1993-09-21 | — | — | US | disclosed |
| US-5166198-A | Herpes virus infections | BEECHAM P.L.C. (GB) | 1992-11-24 | — | — | US | disclosed |
| US-5055458-A | PURINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BEECHAM GROUP P.L.C. (GB) | 1991-10-08 | — | — | US | disclosed |
| EP-0404296-A1 | Phosphono derivatives of purine with antiviral activity | Beecham Group p.l.c. (GB) | 1990-12-27 | — | — | EP | disclosed |
| EP-0353955-A2 | Novel compounds | BEECHAM GROUP PLC (GB) | 1990-02-07 | — | — | EP | disclosed |
| EP-0319228-A2 | Novel compounds | BEECHAM GROUP PLC (GB) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | CHEK1 384/4885PDE4A 64/4885PDE4B 174/4885 |
| US-20250262298-A1 | STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING | STING1, CGAS, TBK1 | CHEK1 34/4885PDE4A 161/4885PDE4B 406/4885 |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | STING1, MAVS, CGAS | CHEK1 381/4885PDE4A 65/4885PDE4B 170/4885 |
| US-11787833-B2 | Modified cyclic dinucleoside compounds as sting modulators | STING1, CGAS, IRF3 | CHEK1 659/4885PDE4A 19/4885PDE4B 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.